Keymed Biosciences Inc. (HKG:2162)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
72.50
-2.75 (-3.65%)
Jul 30, 2026, 3:40 PM HKT

Keymed Biosciences Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Keymed Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $96.12. The average 1-year stock price forecast is 32.58% higher than the current stock price, while the lowest is $85.01 (+17.26%) and the highest is $105.61 (+45.67%).

Price Target: $96.12 (+32.58%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$85.01$96.12$95.24$105.61
Change+17.26%+32.58%+31.37%+45.67%

Analyst Ratings

The average analyst rating for Keymed Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy776678
Buy333444
Hold000000
Sell000000
Strong Sell000000
Total10109101112

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Guotai Haitong
No rating
Guotai Haitong
Buy
Maintains
$138.91
BuyMaintains$138.91+91.60%Jul 10, 2026
Unknown Analyst
Shenwan Hongyuan
No rating
Shenwan Hongyuan
Buy
Maintains
$89.47
BuyMaintains$89.47+23.41%May 28, 2026
Unknown Analyst
Morgan Stanley
No rating
Morgan Stanley
Buy
Maintains
$97.00
BuyMaintains$97.00+33.79%May 28, 2026
Unknown Analyst
KeyBanc
No rating
KeyBanc
Buy
Maintains
$87.31
BuyMaintains$87.31+20.43%Apr 4, 2026
Unknown Analyst
Huatai Securities
No rating
Huatai Securities
Buy
Maintains
$91.08$91.13
BuyMaintains$91.08$91.13+25.70%Mar 30, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
2.51B
from 716.31M
Increased by 250.90%
Revenue Next Year
2.15B
from 2.51B
Decreased by -14.66%
EPS This Year
2.70
from -1.81
EPS Next Year
0.56
from 2.70
Decreased by -79.05%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
110.27M100.06M354.10M428.12M716.31M2.51B
Revenue Growth
--9.26%253.87%20.91%67.31%250.90%
Gross Profit
93.07M97.48M317.22M415.92M627.06M2.28B
Gross Margin
84.40%97.42%89.59%97.15%87.54%90.70%
Operating Income
-360.50M-544.49M-457.43M-626.09M-631.05M352.51M
Net Income
-3.89B-308.12M-359.36M-515.24M-522.64M466.78M
EPS
-----1.812.70
Forward PE
-----23.21
Free Cash Flow
-231.71M-410.26M-714.05M-565.77M-749.94M330.50M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High2.9B
Avg2.5B
Low1.6B

Revenue Growth

Revenue Growth202620272028
High
304.3%
Avg
250.9%
Low
123.1%

EPS Forecast

EPS202620272028
High2.70
Avg2.70
Low2.69

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-